The nose: An underestimated source of Staphylococcus aureus causing wound infection

Journal of Hospital Infection

Volumn 40, Issue SUPPL. B, 1998, Pages

  Casewell, M W ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Hospital infections; MRSA infections; Mupirocin; Nasal carriage; Staphylococcus aureus infections; Wound infection

Indexed keywords

PSEUDOMONIC ACID; TETRACYCLINE;

ANTIBIOTIC PROPHYLAXIS; CONFERENCE PAPER; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DISEASE CARRIER; HEART SURGERY; HEMODIALYSIS; HUMAN; INTRANASAL DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOSE MUCOSA; SEPSIS; STAPHYLOCOCCUS AUREUS; TOPICAL DRUG ADMINISTRATION; WOUND INFECTION;

EID: 0031727284     PISSN: 01956701     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0195-6701(98)90199-2     Document Type: Conference Paper

References (41)

1. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6:87-101.
2. Rafart JV, ed. Prevelancia de las infecciones nosocomiales en los hospitales Espanoles EPINE 1990-1994. Barcelona: Grafimed Publicidad 1995.
3. Williams REO. Healthy carriage of Staphylococcus aureus: its prevalence and importance. Bacteriol Rev 1963; 27: 56-71.
4. Casewell MW, Hill RLR. The carrier state: methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 1986; 18 (Suppl A): 1-12.
5. Kluytmans JAJW. Nasal carriage of Staphylococcus aureus: the key to preventing staphylococcal sepsis. Thesis Rotterdam, Erasmus University 1996; 61-89.
6. Moss B, Squire JR, Topley E. Nose and skin carriage of Staphylococcus aureus in patients receiving penicillin. Lancet 1948; i: 320-325.
7. White A. Relation between quantitative nasal culture and dissemination of staphylococci. J Lab Clin Med 1961; 58: 273-277.
8. White A, Smith J. Nasal reservoir as the source of extranasal staphylococci. Antimicrob Agents Chemother 1963; 30: 675-683.
9. Solberg CO. A study of carriers of Staphylococcus aureus. Acta Med Scand 1965; 178 (Suppl A): A36.
10. Hill RLR, Duckworth G, Casewell MW. Elimination of nasal carriage of methicillin-resistant Staphylococcus aureus with mupirocin during a hospital outbreak. J Antimicrob Chemother 1988; 22: 377-384.
11. Reagan D, Doebbeling BN, Pfaller MA et al. Elimination of coincident Staphylococcus aureus nasal and hand carriage with intranasal application of mupirocin calcium ointment. Ann Intern Med 1991; 114: 101-106.
12. Weinstein HJ. The relation between the nasal-staphylococcal-carrier state and the incidence of postoperative complications. N Engl J Med 1959; 260: 1303-1310.
13. Williams REO, Jevons MP, Shooter RA et al. Staphylococci and sepsis in hospital patients. BM J 1959; ii: 658-662.
14. Calia FM, Wolinsky E, Mortimer JR, Abrams JS, Rammelkamp CH. Importance of the carrier state as a source of Staphylococcus aureus in wound sepsis. J Hyg Camb 1969; 67: 49-57.
15. Williams REO, Noble WC, Jevons MP et al. Isolation for the control of staphylococcal infections in surgical wards. BMJ 1962; ii: 271-282.
16. White A. Increased infection rates in heavy nasal carriers of coagulase-positive staphylococci. Antimicrob Agents Chemother 1963; 30: 667-670.
17. Bassett HFM, Ferguson WG, Hoffman E, Walton M, Blowers RO, Conn CA. Sources of staphylococcal infection in surgical wound sepsis. J Hyg Camb 1963; 61: 83.
18. Coello R, Jimenez J, Garcia P et al. Prospective study of infection, colonization and carriage of methicillin-resistant Staphylococcus aureus in an outbreak affecting 990 patients. Eur J Clin Microbiol Infect Dis 1994; 13: 74-81.
19. Casewell MW. Epidemiology and control of the 'modern' methicillin-resistant Staphylococcus aureus. J Hasp Infect 1986; 7 (Suppl A): 1-11.
20. Casewell MW, Hill RLR. In-vitro activity of mupirocin ('pseudomonic acid') against clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1985; 15: 523-531.
21. Casewell MW, Hill RLR. Elimination of nasal carriage of nasal Staphylococcus aureus with mupirocin ('pseudomonic acid') - a controlled trial. J Antimicrob Chemother 1986; 17: 365-372.
22. Casewell MW, Hill RLR. Mupirocin ('pseudomonic acid') - a promising new topical agent. J Antimicrob Chemother 1987; 19: 1-5.
23. Casewell MW, Hill RLR. Minimal dose requirements for nasal mupirocin and its role in the control of epidemic MRSA. J Hosp Infect 1991; 19 (Suppl B): 35-40.
24. Hospital Infection Society and British Society for Antimicrobial Chemotherapy. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. Report of a Combined Working Party, J Hosp Infect 1990; 16: 351-377.
25. Vanderbroucke-Grauls CM, Frenay HME, van Klingeren B et al. Control of epidemic methicillin-resistant Staphylococcus aureus in a Dutch University Hospital. Eur J Clin Microbiol Infect 1991; 10: 6-11.
26. Coello R, Glynn JR, Gaspar C et al. Risk factors for developing clinical infection with methicillin-resistant Staphylococcus aureus (MRSA) amongst hospital patients initially only colonized with MRSA. J Hosp Infect 1997; 37: 39-46.
27. Mest DR, Wong DH, Shimoda KJ et al. Nasal colonisation with methicillin-resistant Staphylococcus aureus on admission to the surgical intensive care unit increases the risk of infection. Anesth Analg 1994; 78: 644-650.
28. Boelaert JR, de Smedt R, de Baere YE et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infection in haemodialysis patients. Nephrol Dial Transplant 1989; 4: 278-281.
29. Boelaert JR, van Landuyt JW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemia in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-239.
30. Yu VL, Goetz A, Wagener M et al. Staphylococcus aureus nasal carriage and infection in patients on haemodialysis. Efficacy of antibiotic prophylaxis. N Engl J Med 1986; 315: 91-96.
31. Chow JW, Yu VL. Staphylococcus aureus nasal carriage in haemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 1989; 149: 1258-1262.
32. The Mupirocin Study Group. Nasal mupirocin prevents Staphylococcus aureus exit-site infection during peritoneal dialysis. J Am Soc Nephrol 1996; 7: 2403-2408.
33. Kluytmans JAJW, Monton JW, Ijzerman EPF et al. Nasal carriage of Staphylococcus aureus as a major factor for wound infections after cardiac surgery. J Infect Dis 1995; 171: 216-219.
34. Kluytmans JAJW, Mouton JW, Marjolein FQ et al. Reduction of surgical-site infections in cardiothoracic surgery by elimination of nasal carriage of Staphylococcus aureus. Infect Control Hosp Epidemiol 1996; 17: 780-785.
35. Boyce JM. Preventing staphylococcal infection by eradicating nasal carriage of Staphylococcus aureus: proceeding with caution. Infect Control Hasp Epidemiol 1996; 17: 775-779.
36. Rahman M, Noble WC, Cookson B. Mupirocin-resistant Staphylococcus aureus. Lancet 1987; ii: 387.
37. Netto dos Santos KR, de Souza Fonseca L, Gontijo Filho PP. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hos7 pitals. Infect Control Hosp Epidemiol 1996; 17: 813-816.
38. Miller MA, Dascal A, Portnoy J, Mendelson J. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus (MRSA) after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-813.
39. Layton MC, Perez M, Heald P, Patterson JE. An outbreak of mupirocin-resistant Staphylococcus aureus on a dermatology ward associated with an environmental reservoir. Infect Control Hosp Epidemiol 1996; 14: 369-375.
40. Boelaert JR, van Landuyt HW, de Baere YA, Derudder MM, Gordts BZ. What is the risk of resistance during long-term chemoprophylaxis of Staphylococcus aureus bacteremias in hemodialysis by nasal mupirocin? 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 28 September-1 October, 1997: Abstract no. J117.
41. Kluytmans J, Pieper M, Verbrugh H. In vitro susceptibility of Staphylococcus aureus against mupirocin. 20th International Conference on Chemotherapy, Sydney, Australia, 29 June-3 July, 1997: Abstract no. 2301.